200 related articles for article (PubMed ID: 27964938)
1. High-Dose Metformin May Increase the Concentration of Atorvastatin in the Liver by Inhibition of Multidrug Resistance-Associated Protein 2.
Shin E; Shin N; Oh JH; Lee YJ
J Pharm Sci; 2017 Apr; 106(4):961-967. PubMed ID: 27964938
[TBL] [Abstract][Full Text] [Related]
2. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
3. Mrp2 is involved in benzylpenicillin-induced choleresis.
Ito K; Koresawa T; Nakano K; Horie T
Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G42-9. PubMed ID: 15194559
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2.
Liao XY; Deng QQ; Han L; Wu ZT; Peng ZL; Xie Y; Wang GJ; Aa JY; Pan GY
Acta Pharmacol Sin; 2020 Jan; 41(1):129-137. PubMed ID: 31341258
[TBL] [Abstract][Full Text] [Related]
5. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
6. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-associated protein 2 is involved in the efflux of Aconitum alkaloids determined by MRP2-MDCKII cells.
Dai P; Zhu L; Yang X; Zhao M; Shi J; Wang Y; Lu L; Liu Z
Life Sci; 2015 Apr; 127():66-72. PubMed ID: 25744397
[TBL] [Abstract][Full Text] [Related]
8. A membrane vesicle-based assay to enable prediction of human biliary excretion.
Colombo F; Poirier H; Rioux N; Montecillo MA; Duan J; Ribadeneira MD
Xenobiotica; 2013 Oct; 43(10):915-9. PubMed ID: 23402371
[TBL] [Abstract][Full Text] [Related]
9. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Chen C; Mireles RJ; Campbell SD; Lin J; Mills JB; Xu JJ; Smolarek TA
Drug Metab Dispos; 2005 Apr; 33(4):537-46. PubMed ID: 15616150
[TBL] [Abstract][Full Text] [Related]
10. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
[TBL] [Abstract][Full Text] [Related]
11. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport.
Yim CS; Jeong YS; Lee SY; Pyeon W; Ryu HM; Lee JH; Lee KR; Maeng HJ; Chung SJ
Drug Metab Dispos; 2017 Mar; 45(3):246-259. PubMed ID: 28069721
[TBL] [Abstract][Full Text] [Related]
12. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.
Liu L; Cui Y; Chung AY; Shitara Y; Sugiyama Y; Keppler D; Pang KS
J Pharmacol Exp Ther; 2006 Jul; 318(1):395-402. PubMed ID: 16627748
[TBL] [Abstract][Full Text] [Related]
13. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human.
Choi MK; Kim H; Han YH; Song IS; Shim CK
Xenobiotica; 2009 Feb; 39(2):171-81. PubMed ID: 19255943
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.
Fallon JK; Smith PC; Xia CQ; Kim MS
Pharm Res; 2016 Sep; 33(9):2280-8. PubMed ID: 27356525
[TBL] [Abstract][Full Text] [Related]
16. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
17. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) glucuronide, a pharmacologically active metabolite of S-8921.
Sakamoto S; Kusuhara H; Horie K; Takahashi K; Baba T; Ishizaki J; Sugiyama Y
Drug Metab Dispos; 2008 Aug; 36(8):1553-61. PubMed ID: 18474677
[TBL] [Abstract][Full Text] [Related]
18. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
[TBL] [Abstract][Full Text] [Related]
19. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
[TBL] [Abstract][Full Text] [Related]
20. Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class, and its main metabolite, ACU154.
Takada T; Weiss HM; Kretz O; Gross G; Sugiyama Y
Drug Metab Dispos; 2004 Nov; 32(11):1272-8. PubMed ID: 15280219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
